Diabetes medications and cardiovascular outcome trials: Lessons learned

Abstract

The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.